Literature DB >> 24425688

Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?

Jesús F San Miguel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24425688      PMCID： PMC4007943          DOI： 10.3324/haematol.2013.100982

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Authors:  Christof Scheid; Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila el Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Igor Wolfgang Blau; Edo Vellenga; Katja Weisel; Michael Pfreundschuh; Kon-Siong Jie; Kai Neben; Helgi van de Velde; Ulrich Duehrsen; M Ron Schaafsma; Walter Lindemann; Marie José Kersten; Norma Peter; Mathias Hänel; Sandra Croockewit; Hans Martin; Shulamiet Wittebol; Gerard Mj Bos; Marinus van Marwijk-Kooy; Pierre Wijermans; Hartmut Goldschmidt; Henk M Lokhorst
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

2.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

3.  Cellular kinetics in multiple myeloma. A new approach to staging and treatment.

Authors:  S E Salmon; B G Durie
Journal:  Arch Intern Med       Date:  1975-01

Review 4.  Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.

Authors:  Meletios A Dimopoulos; Evangelos Terpos; Asher Chanan-Khan; Nelson Leung; Heinz Ludwig; Sundar Jagannath; Ruben Niesvizky; Sergio Giralt; Jean-Paul Fermand; Joan Bladé; Raymond L Comenzo; Orhan Sezer; Antonio Palumbo; Jean-Luc Harousseau; Paul G Richardson; Bart Barlogie; Kenneth C Anderson; Pieter Sonneveld; Patrizia Tosi; Michele Cavo; S Vincent Rajkumar; Brian G M Durie; Jésus San Miguel
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

Review 5.  Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.

Authors:  Asher A Chanan-Khan; Jesús F San Miguel; Sundar Jagannath; Heinz Ludwig; Meletios A Dimopoulos
Journal:  Clin Cancer Res       Date:  2012-02-10       Impact factor: 12.531

6.  Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

Authors:  J F San-Miguel; P G Richardson; P Sonneveld; M W Schuster; D Irwin; E A Stadtmauer; T Facon; J-L Harousseau; D Ben-Yehuda; S Lonial; H Goldschmidt; D Reece; J Bladé; M Boccadoro; J D Cavenagh; R Neuwirth; A L Boral; D-L Esseltine; K C Anderson
Journal:  Leukemia       Date:  2008-01-17       Impact factor: 11.528

7.  The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Authors:  Meletios Dimopoulos; Adrian Alegre; Edward A Stadtmauer; Hartmut Goldschmidt; Jeffrey A Zonder; Carlos M de Castro; Zvenyslava Masliak; Donna Reece; Marta Olesnyckyj; Zhinuan Yu; Donna M Weber
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

8.  VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

Authors:  Meletios A Dimopoulos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Ofer Shpilberg; Efstathios Kastritis; Martin Kropff; Maria T Petrucci; Michel Delforge; Julia Alexeeva; Rik Schots; Tamás Masszi; Maria-Victoria Mateos; William Deraedt; Kevin Liu; Andrew Cakana; Helgi van de Velde; Jesús F San Miguel
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.